Alkaline phosphatase and hypophosphatasia

José Luis Millán
Sanford Burnham Prebys Medical Discovery Institute
Michael P. Whyte
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs
Please let us know how this document benefits you.

Recommended Citation
https://digitalcommons.wustl.edu/open_access_pubs/5494

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Alkaline Phosphatase and Hypophosphatasia

José Luis Millán1 · Michael P. Whyte2,3

Received: 16 September 2015 / Accepted: 28 October 2015 / Published online: 21 November 2015 © The Author(s) 2015. This article is published with open access at Springerlink.com

Abstract Hypophosphatasia (HPP) results from ALPL mutations leading to deficient activity of the tissue-non-specific alkaline phosphatase isozyme (TNAP) and thereby extracellular accumulation of inorganic pyrophosphate (PPi), a natural substrate of TNAP and potent inhibitor of mineralization. Thus, HPP features rickets or osteomalacia and hypomineralization of teeth. Enzyme replacement using mineral-targeted TNAP from birth prevented severe HPP in TNAP-knockout mice and was then shown to rescue and substantially treat infants and young children with life-threatening HPP. Clinical trials are revealing aspects of HPP pathophysiology not yet fully understood, such as craniosynostosis and muscle weakness when HPP is severe. New treatment approaches are under development to improve patient care.

Keywords Rickets · Osteomalacia · Enzyme replacement · Calcification · Seizures

Introduction

In 1923, Robert Robison, Ph.D. discovered a phosphatase abundant in the skeleton possibly to generate inorganic phosphate (Pi) required to form bone mineral [1]. In 1932, he postulated that an additional but unknown factor regulates skeletal mineralization [2]. This factor would prove to be inorganic pyrophosphate (PPi), a potent inhibitor of mineralization and natural substrate for Robison’s enzyme [3]. The phosphatase, now called tissue-non-specific alkaline phosphatase (TNAP, or TNSALP), is encoded by the ALPL gene [4] expressed richly in bone, liver, and kidney, but also in the central nervous system, fibroblasts, and endothelial and other cell types. Hypomorphic ALPL mutation(s) cause hypophosphatasia (HPP) [4], a rare form of rickets or osteomalacia [5] featuring low serum alkaline phosphatase (ALP) activity and with an incidence for its most severe forms of 1:100,000 [6] and 1:300,000 [7] in the general population [6] of North America and Europe, respectively, but 1 per 2500 births in Canadian Mennonites [8]. The efficacy of enzyme replacement therapy (EzRT) using a mineral-targeted form of recombinant TNAP has been demonstrated for severe HPP [9]. Our review summarizes knowledge concerning TNAP, including revelations about its physiological function coming from investigation of HPP patients and mouse models and successes using EzRT.

The Enzyme

In humans, three genes besides ALPL (ALPI, ALPP, and ALPPL2) encode alkaline phosphatase (ALP) isozymes, but with restricted tissue expression; i.e., “intestinal,” “placent al,” and “germ cell” ALP and are not compromised in HPP [10]. TNAP structure modeling is based on its sequence
Fig. 1 Ribbon representation of the 3D structure of alkaline phosphatase (1EW2) [10]. The active site phosphate (PO₄³⁻) bound to Ser92 during catalysis is shown in green. The three active site metal ions, two Zn²⁺ (Zn1 and Zn2) and one Mg²⁺ (Mg), are shown in white as well as the structural Ca²⁺ ion (Ca). Also indicated are the flexible exposed sequence known as the “crown domain”; the N-terminal helix of one subunit that reaches close to the active site of the contralateral subunit; and the location where the glycosylphosphatidylinositol (GPI) anchor is attached to the C-terminus of the mature enzyme (Color figure online)

homology to the placental isozyme (PLAP) for which crystalllographic coordinates have been determined [11]. TNAP functions physiologically as a homodimer (Fig. 1) [12]. The two monomers become related by a twofold crystallographic axis, with the monomer–monomer interface displaying a strong hydrophobic character with fewer than 30 % of its amino acid residues (hereafter “residues”) involved in hydrogen-bonding interactions [13]. This feature renders the monomer–monomer interface crucial for stability and enzymatic function, and TNAP (and mammalian ALPs in general) is therefore an obligatory homodimer. A flexible surface loop, “the crown domain,” contains residues important for stabilizing the binding of uncompetitive TNAP inhibitors, such as E429 and Y367 [14–16]. Furthermore, this domain contains a low-affinity collagen-binding motif [16]. The N-terminal α-helix (residues 9–25) of each monomeric subunit reaches the active site of the contralateral subunit (Fig. 1) [17]. Both the crown domain and the N-terminal arm help stabilize the dimeric structure and determine allosteric properties [18]. Thus, structural and functional properties explain how some hypomorphic ALPL alleles compromise the kinetic properties of the entire dimer (a dominant-negative effect) leading to TNAP insufficiency and generation-to-generation inheritance of HPP [19]. Three metal-binding sites surrounding the catalytic Ser residue are essential for TNAP enzymatic activity; i.e., M1 and M2 (occupied by Zn²⁺) and M3 (occupied by Mg²⁺) [11, 14]. An additional metal-binding site, M4, apparently occupied by Ca²⁺ and absent in bacterial ALPs, was revealed by solving the 3D structure of PLAP [11, 20]. However, this M4 structural metal site does not influence TNAP catalytic activity [21]. During TNAP-mediated catalysis, Zn²⁺ ions occupy the M1 and M2 sites, Mg²⁺ the M3 site, and Ca²⁺ the M4 site. With skeletal mineralization, the increasing Ca²⁺ gradient in the extracellular matrix first activates TNAP by replacing the Mg²⁺ with Ca²⁺ at M3, but at high Ca²⁺ concentrations, it gradually deactivates TNAP as Ca²⁺ competes out the Zn²⁺ from the M1 and M2 metal sites [21]. This explains why TNAP loses activity at the completion of the mineralization process [22].

Thus, ALPL mutations that alter residues at the monomer–monomer interface, the crown domain, the N-terminal arm, and the divalent cation-binding sites can all cause HPP [20]. Additionally, post-translational modifications of TNAP are important. TNAP (indeed all mammalian ALPs) is bound to the surface of plasma membranes via a glycosylphosphatidylinositol (GPI) anchor that enables movement of the enzyme by enhancing membrane fluidity [23]. This GPI anchor can be cleaved by the enzymatic action of phospholipases found in plasma membranes, perhaps explaining how TNAP is released into the circulation and other biological fluids [24]. Also, TNAP contains five putative N-linked glycosylation sites, N123, N213, N254, N286, and N413 [25], with the sugar chains required for catalytic activity [26]. The types of sugars in TNAP explain the different biophysical and kinetic properties of its “isoforms” produced by bone, liver, kidney, and vascular cells [27].

In vitro, TNAP has broad substrate specificity and can hydrolyze or transphosphorylate a considerable variety of compounds [10]. However, only a few [inorganic pyrophosphate (PPi), pyridoxal 5’-phosphate (PLP), and likely phosphoethanolamine (PEA)] are natural substrates for TNAP based on studies of HPP patients and fibroblasts and Alpl knockout (KO) mice [28, 29]. Nevertheless, it is unclear what metabolic pathway leads to PEA accumulation [27, 29]. Recent studies also suggest that ATP [30–32], di-phosphoryl lipopolysaccharide (LPS) [33], and phosphorylated osteopontin (p-OPN) [34] are natural substrates of TNAP.

The Disease

HPP features extraordinarily broad-ranging severity (Fig. 2), but all patients carry one or two loss-of-function mutations in their ALPL alleles [4, 35, 36]. Traditionally, HPP is classified in the clinic firstly by whether there are dental manifestations alone (i.e., without skeletal disease or other complications), and then according to the patient’s age when any additional complications initially manifested. Thus, in order of decreasing severity, clinicians
recognize perinatal HPP, infantile HPP, childhood HPP, adult HPP, and odonto-HPP [35]. Perinatal HPP is detectable in utero using fetal sonography, and can cause stillbirth or be fatal soon after [37]. Infantile HPP presents before 6 months-of-age, often with rickets, failure-to-thrive, hypotonia, and muscle weakness, and can be complicated by hypercalcemia, nephrocalcinosis, vitamin B₆-dependent seizures, and craniosynostosis [5, 38]. Vitamin B₆-dependent seizures and skeletal deterioration predict death from respiratory complications [36]. If there is survival beyond infancy, deciduous teeth are lost prematurely (i.e., before the patient’s 5th birthday) because insufficiently mineralized cementum can not anchor their roots to the periodontal ligament [39]. Childhood HPP also has broad-ranging severity, but almost always includes premature loss of primary teeth. Rickets sometimes causes short stature, and skeletal deformities can include bowed legs and bony enlargement near joints due to widened metaphyses. Affected children often manifest some degree of motor impairment and fatigue easily. In 2015, “mild” versus “severe” childhood HPP were distinguished [36]. In occasional cases, childhood HPP presents in the guise of chronic recurrent multifocal osteomyelitis, possibly due to marrow edema secondary to pyrophosphate crystal deposition [40]. Adult HPP usually presents during middle age and features osteomalacia, although some patients report a history of rickets and/or early loss of “baby” teeth [41]. Recurrent, poorly healing, metatarsal stress fractures and then pseudofractures are typical skeletal complications. Some of these patients suffer calcium pyrophosphate dihydrate (CPPD) crystal deposition (chondrocalcinosis), PP₆ arthropathy including attacks of pseudogout, or sometimes calcific periarthritis [42]. Odonto-HPP is diagnosed when the only clinical abnormality is dental disease, with radiological and biopsy studies revealing no evidence of rickets or osteomalacia. Figure 2 shows representative radiographic images of the skeleton in these principal forms of HPP.

HPP is a remarkable type of rickets or osteomalacia because circulating levels of calcium, P₆, and vitamin D metabolites are not low. Instead, there is a block of mineral entry into the skeleton [35].

At this writing, 300 ALPL mutations have been identified in HPP, 70 % of which are missense (http://www.
Radiographic bone abnormalities appeared at both had elevated urinary PEA and PP i and plasma PLP of age, and osteopenia and fractures worsened thereafter. Their lifespan averaged 8.8 ± 3.4 days on the 129J background, and 10.6 ± 3.4 days on the 129J, C57Bl/6J hybrid background. Plasma of WT mice and are truncated, inactive TNAP having 276 residues rather than the 525 WT residues. However, some correct splicing was detected, suggesting the mutation is hypomorphic. These mice have low plasma ALP activity and late-onset skeletal abnormalities, but a normal life span and no epilepsy.

Mouse Models of HPP

In the 1990’s, two Alpl global KO mouse models for HPP (Alpltm1Sor and Alpltm1Jlm), that differ in the design of the targeting construct, were developed independently by the research groups of Soriano [43] and of Millán [44]. In Alpltm1Sor KO mice, the genomic Alpl sequence spanning from the middle of exon 2 to the middle of exon 6 was replaced with a LacZ-Neo cassette to enable expression of β-galactosidase under control of the endogenous Alpl promoter. These mice had elevated plasma PLP levels and died from seizures caused by diminished hydrolysis of PLP to pyridoxal (PL) and thus deficient PL availability for cells of the central nervous system [45]. Surviving animals manifested dental dysplasia [43]. In contrast, the Alpltm1Jlm KO model was generated by inserting a Neo cassette into the middle of exon 2 to the middle of exon 6. Homozygous animals exhibited vitamin B6-dependent seizures and impaired bone mineralization [44]. Their lifespan averaged 8.8 ± 2.3 days on the 129J background, and 10.6 ± 3.4 days on the 129J, C57Bl/6J hybrid background. Plasma of Alpl KO mice contains little ALP activity, which comes from the gut [46], whereas heterozygous Alpl+/− mice have approximately 50 % the plasma ALP activity of wild-type (WT) mice and are healthy and fertile [44].

In 1999, these two KO mouse models, Alpltm1Sor and Alpltm1Jlm, were further characterized and compared [28]. Radiographic bone abnormalities appeared at ~10 days-of-age, and osteopenia and fractures worsened thereafter. Both had elevated urinary PEA and PP i and plasma PLP levels. That same year, Beertsen et al. [47] reported a 2–3 day delay in incisors eruption and onset of mineralization of the mantle dentin within the developing molars of the Alpltm1Sor KO mice. In contrast, the dentin and enamel developed normally, except for some localized hypoplasia. The most conspicuous finding, however, involved the acellular cementum along the molar roots, which deposited as thin and irregularly shaped patches rather than a continuous layer around the base of the periodontal ligament fibers [47]. The Alpltm1Jlm KO mice had impaired dentin mineralization in the incisor and molar roots, ranging from a mild delay to severely disturbed dentinogenesis. Subsequently noted were lack of acellular cementum [48, 49] and disrupted organization of the rods and inter-rod structures in the enamel [50]. Also, premature fusion of the coronal suture (craniosynostosis) appeared in these Alpltm1Jlm KO mice [51]. Figure 3 shows representative radiographic images of their skeletal and dental phenotype. Alpltm1Jlm KO mice also have an apoptotic thymus, thin descending nerve roots, leukopenia, and gas accumulation in their small intestine [44, 52]. Most studies concerning murine HPP and the preclinical work for EzRRT for HPP used Alpltm1Jlm mice. Accordingly, later, we simply refer to them as the KO mice.

Now, other Alpl mutant mouse lines have been generated, although their skeletal and dental phenotypes remain to be determined. In 2009, the AlplALPLD1 model was produced by ENU mutagenesis and carries an A to G mutation at nucleotide (nt) position 326 in exon 5 [53]. This causes an Asp to Gly change at residue 109. In 2012, Sabrautzki et al. reported new mouse models for various metabolic bone diseases produced by the Munich ENU Mutagenesis Project [54], including phenotypes associated with lowered plasma ALP activity due to mutations in Alpl. AlplRAP23 carries a missense T to G mutaton in exon 7 at nt 755 (Leu to Pro at residue 251). AlplRAP026 has a splice-site mutation in intron 9. AlplRAP027 carries a T to A mutation in exon 10 at nt 1194 (Ile to Asn at residue 395). AlplRAP032 has an A to G mutation in exon 11 at nt 1217 (Asp to Gly at residue 406). The homologous mutation had been found in an HPP patient. AlplSAP007 has an A to G point mutation in exon 12 at nt 1357 (Thr to Ala at residue 453).

Currently, mouse models of adult HPP are receiving attention. In 2007, the Gena 328 mouse, AlplHpp, from ENU mutagenesis exhibited autosomal semi-dominant adult HPP [55]. A point mutation at the splice site for exon 8 produced a truncated, inactive TNAP having 276 residues rather than the 525 WT residues. However, some correct splicing was detected, suggesting the mutation is hypomorphic. These mice have low plasma ALP activity and late-onset skeletal abnormalities, but a normal life span and no epilepsy.

The first murine model of odonto-HPP harbors a missense mutation (c.346G>A) that changes codon 116 from Ala to Thr as identified in a kindred with AD odonto-HPP [56]. These Alpl+/A116T mice have ~50 % WT plasma ALP activity and no differences versus WT mice in litter size, survival, or body weight. Their postcranial skeleton is normal radiographically, including no differences in femur length, cortical or trabecular structure or mineral density, or mechanical properties. However, their alveolar bone has radiolucencies and resorptive lesions and osteoid accumulation on the crest. Non-significant changes in acellular cementum seem not to affect periodontal attachment, although circulating ALP activity correlates significantly with incisor cementum thickness.
Now, two murine models of adult HPP reflect conditional ablation of *Alpl* in chondrocytes and osteoblasts together (*Prx1-Cre; Alpl*^floxflo^) or in osteoblasts alone (*Col1a1-Cre; Alpl*^floxflo^) (manuscript in preparation). Their phenotype compared to KO and *Alpl^−/−^* mice is summarized in Table 1.

**Pathophysiology of HPP**

In the skeleton, TNAP is confined to the surface of osteoblasts and chondrocytes, including their shed matrix vesicles (MVs) [57, 58] where the enzyme is particularly enriched [59]. In humans and mice with HPP (vide infra), electron microscopy revealed that TNAP-deficient MVs contain hydroxyapatite (HA) crystals, but extravesicular growth of these crystals is blocked (Fig. 4) by the extracellular accumulation of PPi [3, 60–62]. Elevated urinary and plasma levels of PPi were discovered in the 1960s [63–65]. Indeed, breeding *Alpl* KO mice to mice deficient in either the extracellular production of PPi (*Enpp1−/−*) or transport extracellularly (*ank/ank*) of PPi normalized extracellular levels of PPi. This prevented skeletal disease in the double KO mice, and affirmed PPi accumulation as the cause of the rickets/osteomalacia in HPP [66, 67]. The effect of the double ablation was partial at some skeletal sites, likely reflecting variations of *Enpp1* expression [62, 66].

In the KO mice, ATP-dependent 45Ca precipitation was reduced within calvarial osteoblast-derived MVs and attributed to increases within the MV of PPi from impaired hydrolysis [68]. However, TNAP is not only a PPiase but, on MVs, is also a potent ATPase [31, 69]. Indeed, Yadav et al. showed that combined ablation of TNAP and
Table 1 Murine models of HPP spanning the severity of the disease

<table>
<thead>
<tr>
<th>Manifestations</th>
<th>Alpl&lt;sup&gt;−/−&lt;/sup&gt;</th>
<th>Alpl&lt;sup&gt;Prx1/Prx1&lt;/sup&gt;</th>
<th>Alpl&lt;sup&gt;Col1/Col1&lt;/sup&gt;</th>
<th>Alpl&lt;sup&gt;B/A1167&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seizures</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Perinatal death</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Rickets or osteomalacia</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Joint defects</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Alveolar bone hypomineralized</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Absence of acellular cementum</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Cellular cementum hypomineralized</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Dentin (molar) hypomineralized</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Dentin (incisor) hypomineralized</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Enamel defects</td>
<td>Yes</td>
<td>?</td>
<td>?</td>
<td>Yes</td>
</tr>
<tr>
<td>Craniosynostosis</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Nephrocalcinosis</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

?: not yet studied

---

Fig. 4 Mechanisms of initiation and propagation of skeletal mineralization. Scanning electron microscopy images of matrix vesicles (MV) displaying mineral confined to the interior of the vesicles (a), with mineral breaking through the MV membranes (b) and with mineral propagating onto the collagenous scaffold (c). d Diagram detailing our current understanding of the biochemical bases for these three steps of MV-mediated initiation of biomineralization. MVs appear to initiate HA mineral deposition by accumulation of P<sub>i</sub> generated intravesicularly by the action of PHOSPHO1 on phosphocholine and also via P<sub>T</sub>-1-mediated incorporation of P<sub>i</sub> generated extravesicularly by TNAP or NPP1. The extravesicular propagation of mineral onto the collagenous matrix is mainly controlled by the pyrophosphatase activity of TNAP that restricts the concentration of this potent mineralization inhibitor and establishes a PP<sub>i</sub>/P<sub>i</sub> ratio conducive for controlled calcification. Additionally, osteopontin (OPN), another potent mineralization inhibitor that binds to HA mineral as soon as it is exposed to the extracellular fluid, also controls the degree of extracellular matrix mineralization. Both elevated levels of PP<sub>i</sub> and phosphorylated OPN are found in HPP mice. ECM extracellular matrix, HA hydroxyapatite, OPN osteopontin
PHOSPHO1 is additive and leads to the lack of HA crystal formation within MVs, the absence of skeletal mineralization, and embryonic lethality. PHOSPHO1 generates P_i inside MVs thus contributing to the initiation of HA mineral formation in the intravesicular space [70]. TNAP is a PPase crucial for allowing extravesicular growth of HA crystals, while also generating P_i from the hydrolysis of PP_i and acting as an extracellular ATP phosphohydrolase that generates P_i in the perivesicular space. Thus, current understanding of TNAP function supports Robison’s hypothesis concerning skeletal mineralization [35, 70, 71]. NPP1, the enzyme that when on the cell surface produces PPase in the MV microenvironment, and may act as a phosphatase in the absence of TNAP [30, 69–71]. Thus, NPP1 could be a modifier of the HPP phenotype, at least in mice. In fact, PHOSPHO1-deficient mice have increased plasma PP_i levels caused by reciprocal reduction of TNAP activity and increased NPP1 expression, as well as accumulation in the circulation of phosphorylated OPN, an inhibitor of mineralization that perhaps exacerbates the rickets/osteomalacia and fracturing of HPP.

Because PHOSPHO1 modifies the HPP phenotype in KO mice, we have searched for Phospho1 gene mutations in patients with HPP-like disease without ALPL mutations, however, thus far with negative results. Accordingly, the hypotheses proposed by Robison for skeletal mineralization [1, 2]: (i) TNAP as a P_i-generating enzyme, and (ii) an unknown factor controlling the supersaturated milieu for mineralization (now recognized to be PP_i), are validated by current data stemming largely from investigations of HPP [35, 72–75]. Furthermore, we currently appreciate that there are interactions between PHOSPHO1, NPP1, and TNAP during MV-mediated calcification: the first step is a convergence of two independent biochemical pathways: intravesicular P_i generation by the enzymatic action of PHOSPHO1, and the influx via P_i transporters of P_i generated in the perivesicular space by the enzymatic actions of TNAP and NPP1 (Fig. 4).

Another natural substrate of TNAP discovered by studying HPP patients is PLP, the major circulating form of vitamin B_6. Vitamin B_6, mediated by its various vitamers, is a cofactor for at least 110 enzymes. The three vitameric forms, pyridoxal (PL), pyridoxamine (PM), and pyridoxine (PN), can all be phosphorylated by PL kinase to their 5’-derivatives, PLP, PMP, and PNP, respectively [76, 77]. PLP is a coenzyme for the catabolizing of various amino acids, and for decarboxylations necessary for neurotransmitter generation including dopamine, serotonin, histamine, taurine, and gamma-aminobutyric acid (GABA). PLP and PMP are interconvertible through aminotransferases or PMP/PNP oxidase. Removal of P_i from PLP to form PL is one important function of TNAP [78]. Only the non-phosphorylated vitamers can enter cells, and once inside the cells, these non-phosphorylated vitamers are converted back to PLP to be used as a coenzyme for various enzymatic pathways. TNAP deficiency increases plasma PLP levels in all HPP patients, but leads to low levels of PL in the circulation in severely affected infants who consequently have insufficient incorporation of PL into the CNS and therefore vitamin B6-dependent seizures [45, 78–80]. Resembling the 100 % lethality when vitamin B_6-dependent seizures occur in infantile HPP [38], KO mice too have 100 % mortality after weaning, always heralded by seizures. TNAP is highly expressed in the developing murine neural tube [81] and certain areas of the mature brain [82]. The absence of TNAP in KO mice is associated with hypomyelination and thinning of spinal nerves, the absence of myelinated axons, and an increased proportion of immature cortical synapses [44, 52, 83]. Matching clinical experience treating vitamin B_6-dependent seizures in HPP, injection or ingestion of PL, a hydrophobic form of vitamin B_6 that traverses biological membranes temporarily suppresses the epilepsy of KO mice [43, 44, 52].

PEA is elevated in the blood and urine of patients with HPP [28, 29, 45], but its endogenous origin is uncertain. PEA is a component of the cell-surface glycosylphosphatidylinositol link for proteins, including TNAP. However, an additional or alternative source of PEA may reflect diminished hepatic O-phosphorylethanolamine phospho-lyase (PEA-P-lyase) activity—the enzyme reported to hydrolyze PEA using PLP as a cofactor [84–86]. Because TNAP hydrolyzes extracellular PLP to PL to allow incorporation of PL into cells for the formation of PLP needed as a coenzyme, insufficient PLP inside hepatic cells could increase PEA accumulation. In this regard, the authors began their nearly career-long collaborations in 1979 when they studied a large multigenerational kindred with adult HPP who showed elevated PEA and phosphoserine levels in the urine which correlated inversely with serum total and liver TNAP activity, but not serum bone TNAP activity [87].

TNAP KO mice have high plasma osteopontin (OPN) levels encoded by Spp1, and elevated expression of its RNA in cultured osteoblasts [88–90]. Although the function of OPN is incompletely understood, it anchors osteoclasts to HA by its poly-aspartate sequences, while also binding CD44 and α_3β_3 integrin via its RGD sequence, thus mediating cell signaling and/or migration [91]. OPN is a highly phosphorylated glycoprotein, with 36 serine/threonine phosphorylation sites [92]. This phosphorylation is important because OPN’s inhibitory effect on mineral deposition diminishes if 84 % of this covalently bound phosphate is removed [93]. Phosphorylated, but not dephosphorylated, OPN inhibits mineralization in vascular smooth muscle cells [94]. Certain phosphorylated OPN
peptides also inhibit HA formation in vitro [95], and cause dose-dependent inhibition of mineralization by cultured cells [96]. Extracellular PP, levels control OPN expression by cultured osteoblasts [91, 96], and high plasma levels of phosphorylated OPN accompany the increased extracellular PP, levels in Alpl KO mice [90]. In turn, [Alpl−/−; Spp1−/−] double KO mice have partial improvement of the hypomineralization compared to Alpl−/− KO mice [90]. Hence, phosphorylated OPN accumulation may contribute to the impaired bone mineralization of Alpl KO mice. Absent TNAP function leads to accumulation of phosphorylated OPN. This suggests that OPN is another potent inhibitor of mineralization, with elevated PP, and comparable changes in PP and OPN expression levels.

What We Don’t Yet Understand About HPP

Premature fusion of cranial sutures (craniosynostosis) in HPP and other forms of rickets may seem counter-intuitive and remain unexplained. Patients with severe HPP receiving asafotase alfa still often require craniotomies [101] to relieve intracranial pressure. However, asafotase alfa [102] and ChimAP [103] (a soluble chimeraic form of human ALP), both can prevent craniosynostosis, at least in mice (vide infra), if treatment starts at birth. So, prevention of craniosynostosis may depend on the time of initiation of the treatment, although there are data to indicate that in humans craniosynostosis may begin during embryonic life [104]. Thus, clarifying the onset and mechanism of craniosynostosis may help design interventions at a developmental stage when enzyme replacement may not be feasible in patients.

While the role of TNAP in the skeleton seems well understood, little is known about its function in the kidney, despite reference to this ALP isozyme as liver/bone/kidney type ALP. Expression of TNAP in the kidney may seem counter-intuitive because TNAP hydrolyses PP, a potent mineralization inhibitor that could help prevent kidney stones. In fact, reduced urinary PP, predisposes to nephrolithiasis [105]. PP,creatinine ratios were reduced in 107 patients with recurrent calcium kidney stones [106]. PP, levels in urine are >10 μM compared to plasma concentrations of approximately 1-6 μM that mainly arise from liver metabolism [107]. Intravenous 32PP is rapidly hydrolyzed in plasma, with PP also being filtered at the glomerulus and subject to further hydrolysis within the kidney; <5 % of intravenous 32PP appears in urine. These data indicate that PP in the kidney likely originates locally. Thus, nephrolithiasis despite high urinary concentrations of PP, in severely affected babies with HPP could seem puzzling, but their severe hypercalcemia and hypercalciuria is likely the key factor. Interestingly, children and adults with HPP are often hyperphosphatemic with increased TmP/GFR, suggesting kidney TNAP plays a role in P, excretion [36].
Supportive Management of HPP

HPP management has been, until very recently, supportive [9]. Bone-targeted enzyme replacement therapy (asfotase alfa, now Strensiq™) was approved for HPP in Japan (July, 2015), and for pediatric-onset HPP in Canada (August, 2015), Europe (August, 2015), and the USA (October, 2015). Supportive treatment includes hydration and restriction of dietary calcium and perhaps administration of calciuercetics for infants with hypercalcemia and hypercalciuria [35, 36]. Management of the respiratory complications of perinatal and infantile HPP may be complex as multiple factors compromise their pulmonary function [108]. Vitamin B₆-dependent seizures can respond temporarily to pyridoxine administration. Craniosynostosis may need surgical intervention. Fractures can mend, but often slowly and requiring prolonged casting or stabilization with intramedullary hardware. Femoral pseudofractures can also respond to intramedullary rodding [109]. Dental manifestations can be helped by a knowledgeable dentist.

Targeting TNAP to Bone Mineral

Bolstered by insight derived from discovery of elevated plasma PLP levels in HPP [45] that predicted TNAP is cell-surface anchored, intravenous administration of ALPs to HPP patients was attempted to decrease extracellular PP₃ levels and thereby improve skeletal mineralization. However, experience with such EzRT, including plasma from patients with Paget bone disease containing high bone TNAP activity, proved unsuccessful [110]. A 6-month-old girl with worsening infantile HPP repeatedly given intravenous infusions of TNAP-rich plasma obtained by plasmapheresis from two men with Paget bone disease showed circulating ALP activity with a half-life of ~2 days that persisted during a 5-week period of six ALP infusions. Sequential radiographic studies were interpreted as showing arrest of worsening rickets with slight reminer alization of metaphyses, although urinary levels of PEA and PP₃ seemed unaltered [110]. However, three subsequent patients deteriorating from infantile HPP [111] and given similar infusions of Paget plasma showed no radiographic or other benefit. Discouraging findings also occurred with attempted EzRT using purified human liver TNAP [112] and purified PLAP [113]. The cumulative findings indicated necessity for increasing TNAP activity in situ in the skeleton to reverse the pathophysiology of HPP. This hypothesis was supported in 2003 and 2007 by rescue with radiographic improvement demonstrated by two unrelated girls with life-threatening infantile HPP following attempts to transplant healthy mesenchyme-derived marrow cells, hoping TNAP-replete donor osteoblasts or chondrocytes might engraft in their skeletons [114, 115]. Subsequently, a woman with adult HPP carrying the most common American ALPL mutation seemed to benefit from teriparatide injections given to increase TNAP biosynthesis by her osteoblasts [116]. Then, anabolic treatment with parathyroid hormone 1-34 or 1-84 benefitted some adults with HPP [117–119], but not others [120, 121]. Parathyroid hormone therapy is not sanctioned for children, because osteosarcoma appeared in growing rats given teriparatide [122]. Evaluation of anti-sclerostin antibody (BPS804) therapy, which has been reported to increase bone-specific ALP when administered to healthy post-menopausal women [123] (www.clinicaltrials.gov identifier NCT01406977), was not carried forward. Anabolic approaches may favor patients with heterozygous ALPL mutations, because the WT ALPL allele is intact for upregulation; however, it will probably not be useful for severe AR HPP with at best “more of a bad enzyme.”

In 2005, Enobia Pharma, Montreal, Canada bio-engineered and then expressed in Chinese hamster ovary (CHO) cells a first-in-class mineral-seeking recombinant TNAP to treat HPP. This biologic reflected in tandem the coding sequences for (i) soluble human TNAP, by excluding the hydrophobic C-terminal GPI anchoring motif (i.e., soluble TNAP: sALP), (ii) the Fc region of human IgG gamma-1 (Fc) to facilitate purification and prolong the circulating half-life, and (iii) ten acidic aspartate residues (D₁₀) for selective drug delivery to bone [124–126]. The resulting 726-amino acid fusion protein was initially designated sALP-FcD₁₀ to indicate its different domains (Fig. 6), renamed ENB-0040 when produced under Current Good Manufacturing Practice (cGMP), and asfotase alfa after clinical trials began. Alexion Pharmaceuticals, Cheshire, CT acquired Enobia Pharma in 2012. Asfotase alfa is now also called Strensiq™.

Preclinical Evaluation of Bone-Targeted EzRT for HPP

Preclinical testing of sALP-FcD₁₀ primarily involved Alp⁺¹⁺¹⁻¹⁻ (KO) mice. Pharmacokinetics (PK) and tissue distribution evaluations included newborn and adult mice and comparisons of different routes of administration [127]. Histochemical staining confirmed localization and catalytic activity of sALP-FcD₁₀ in bone tissue (Fig. 6).

The first study involved newborn KO mice given subcutaneous (SC) injections for 15 days, then investigated with micro-computed tomography (µCT) of the calvarium and proximal tibial growth plate [127]. At 2 mg/kg daily, general appearance, body weight, and tail length improved with normal growth. At 8.2 mg/kg daily, body weight was
greater than control mice, and plasma PP i concentrations were normal. sALP-FcD10 minimized hypomineralization in the feet and reduced the number of mice with severely dysmorphic rib cages. The hind limbs appeared healthy in all treated animals [127]. A 52-day study of daily SC injections of 8.2 mg/kg also showed normal plasma PL and calcium concentrations and prevention of skeletal defects and epilepsy with good survival [127]. Hypomineralization of dentin and alveolar bone was also prevented and acellular cementum now formed properly [48, 49]. Immunohistochemical staining for OPN revealed unremarkable, rather than absent, acellular cementum on root surfaces [48]. The KO mouse dentin defect results from inability of MV-initiated mineralization foci to expand into a mineralization front, and varies from delayed mineralization to arrest of mantle dentin mineralization together with lack of circumpulpal dentin and odontoblast differentiation defects [49]. The OPN accumulation likely contributes to the impaired mineralization of mantle dentin. Early treatment with sALP-FcD10 enabled dentinogenesis and molar mineralization.

Then, the relationship was defined between sALP-FcD10 doses and therapeutic responses after 43 days [128] (Fig. 7). Endpoint assessments included survival, body weight, tibial and femoral length, and bone mineralization in the feet, rib cage, and lower limbs assessed radiographically. Radiographs, μCT, and histomorphometry evaluated skeletal mineralization. Daily dose correlated clearly with the percentage of normal feet, rib cages, and lower limbs. An effective dose was established for 80% of the mice (ED80 of 3.2, 2.8, and 2.9 mg/kg/day for feet, rib cage, and lower limbs, respectively. The ED80, along with serum ALP activity and sALP-FcD10 PK data were used to estimate the minimum effective dose for these KO mice. Further studies then validated the mineral targeting, including to sites notorious for poor vascularity, e.g., the enamel organ during tooth development. Untreated KO mice showed with scanning electron microscopy disorganization of the rod and inter-rod structures of enamel. Histology revealed enamel hypomineralization both in molars and incisors, loss of polarization of ameloblasts important for enamel matrix formation, and even absent enamel. What was now called ENB-0040 reached the enamel organ during its secretory and maturation phases [50]. μCT showed, with treatment to age 23 days, dose-dependent improvements of absolute and relative enamel volumes. Notably, odonto-HPP typically manifests the mildest reductions of serum ALP levels [35], usually
explained by dominant inheritance of a single mutated ALPL allele [19], and reveals that tooth formation, especially cementogenesis, is the developmental process most sensitive to TNAP function, involving changes in the local Pi/PPi ratio [129, 130]. ENB-0040 treatment preserved acellular cementum formation in the KO mice, supporting this premise [48] and that the structural integrity of enamel by the enamel organ is directly regulated by extracellular PPi concentrations [50]. TNAP is highly expressed in mature odontoblasts, and the molar and incisor roots of KO mice feature dentin hypomineralization ranging from mild to severe. Lack of mantle dentin mineralization accompanies disordered and dysmorphic odontoblasts. However, in KO mice, the formation of initiation of mineralization within, and rupture of MVs in dentin matrix are not compromised. ENB-0040 corrected the defective dentin mineralization in the molar roots [49]. Liu et al. [51] showed that these mice by age 3 weeks have craniofacial shape abnormalities suggestive of limited anterior–posterior head growth with craniosynostosis (i.e., bony coronal suture fusion). μCT isosurface images showed ENB-0040 8.2 mg/kg/day from birth prevented at age 15 days craniofacial bone mineralization defects and premature suture fusion. In untreated KO mice, multiple cranial vault and facial bones lacked adequate mineralization on μCT that was not evident in the treated mice. Digital caliper linear measurements demonstrated that treatment improved nose length, nasal bone length, and frontal bone length [102].

Clinical Trials Using Mineral-Targeting TNAP in Pediatric HPP

In June 2008, an Investigational New Drug (IND) application to test ENB-0040 for HPP patients was filed by Enobia Pharma. Initial dosing was based partly on (i) dose-response data in KO mice [128], (ii) efficacy observed in treated mice that achieved an equivalent to serum ALP activity in the range of 2400–6000 U/L; (iii) the No-Observed-Adverse-Effect Level (NOAEL) in more sensitive species (rats and monkeys) established in 1-month IV toxicity studies, and 1-month IV/SC bridging and tolerability studies in rats; and (iv) a safety factor of 10 applied to the NOAEL.
The first results in HPP patients were from an open-label, multicenter, dose-escalating phase 1 study of the safety, tolerability, and pharmacology of ENB-0040 in six adults with HPP (www.clinicaltrials.gov identifier NCT00739505). They received one dose iv of 3 mg/kg, and then 1 or 2 mg/kg sc once weekly for 3 weeks. The first full report concerning HPP treatment was from an open-label, multicenter, international study published in 2012 [9]. It evaluated the safety, tolerability, bioavailability, PK, pharmacodynamics, and efficacy of asfotase alfa given for nearly 1 year to infants and young children ≤3 years-of-age with life-threatening perinatal and infantile HPP. Before treatment, one 3-year-old girl had lost nearly all radiographically apparent skeletal mineral. The Supplementary Appendix to that paper provides a detailed description of each patient [9]. Efficacy assessments included changes in radiographic scales to evaluate the characteristic skeletal findings, gross and fine motor function, cognitive development, and pulmonary complications and their management. Asfotase alfa was administered as a single iv infusion of 2 mg/kg, followed by sc injections of 1 mg/kg thrice weekly for 24 weeks, with an extension study thereafter. The sc dose could be increased up to 3 mg/kg for worsening failure-to-thrive, deteriorating pulmonary function, or no radiographic evidence of skeletal improvement [9]. Of eleven recruited patients, parents withdrew one because she had a moderate adverse reaction during the iv infusion. One infant who completed the first 6 months of treatment died soon after from pneumonia and sepsis judged unrelated to the study drug. Of the nine patients treated for 1 year, four represented perinatal HPP and five represented infantile HPP. Typically, serum calcium levels were elevated (most had nephrocalcinosis), and dietary calcium had been restricted in all but one patient. During treatment, substantial radiographic improvement in skeletal abnormalities was documented at week 24 in all but one patient, with continued healing through week 48. The girl with the most extreme skeletal disease eventually improved with calcification apparent after 9 months of therapy and the delay probably reflecting her profound deficit of skeletal mineral. The radiographic improvement is illustrated for the oldest patient (3 years old) (Fig. 8), and for the youngest patient (<1 month old) (Fig. 9). Positive mineral balance throughout the skeleton was obvious radiographically, sometimes after several weeks or months, and involved diffusely membranous as well as enchondral bone. Symptomatic hypocalcemia from "hungry-bones" did not occur, but serum calcium decreased in some patients, consistent with improved uptake of calcium into mineralized bone. Increases in serum parathyroid hormone levels called for liberalization of dietary calcium intakes [9]. Deciduous teeth erupted in all the patients during therapy, with only one patient subsequently having HPP-related tooth loss [9]. Management of perinatal HPP in particular is critically dependent on early diagnosis [131]. An important concern is that some clinical laboratories do not flag as abnormal low serum ALP and this can delay the diagnosis and increase the risk of severe respiratory morbidity. Institution of EzRT should also not be delayed in order to correct any vitamin D deficiency—this can be accomplished contemporaneously if necessary.

Subsequently, asfotase alfa was given for 5 years to 12 children who were 5–12 years of age at study entry and substantially impaired by HPP [132]. Two radiographic scales to quantitate HPP skeletal disease documented rapid and significant improvement at 6-months of treatment, including comparisons to serial radiographs from similarly affected historical controls. Further improvements included patient growth, strength, motor function, and agility that achieved normal values for age- and gender-matched peers and were sustained at 5 years of therapy. Pain and disability resolved for most patients [132]. Mild-to-moderate injection site reactions were common, and sometimes associated with lipohypertrophy. Low titers of anti-asfotase alfa antibodies were noted in all. No evidence emerged for clinically significant ectopic mineralization or resistance to the treatment [132].

**Future Treatments for HPP**

Kiffer-Moreira et al. recently evaluated ChimAP in KO mice. ChimAP is a chimeric ALP engineered by substituting the flexible crown domain of human IAP by that of human PLAP [133]. A clinical study is currently underway to assess ChimAP for treating acute kidney injury (www.clinicaltrials.gov identifier NCT02182440). Daily SC injections of ChimAP to KO mice at doses of 1, 8, or 16 mg/kg from birth to age 53 days were associated with normal lifespan and body weight and prevention of vitamin B6-dependent seizures at 16 mg/kg/day [103]. Radiographs, μCT, and histological analyses documented sustained mineralization of cortical and trabecular bone and secondary ossification centers in long bones. Craniosynostosis was prevented, and no evidence emerged of ectopic calcification by radiography and histology of the aorta, stomach, kidneys, or lungs [103]. AM Pharma (Bunnik, The Netherlands) has recently received FDA and EMA orphan drug designation for investigation of ChimAP (RecAP) for HPP. Daily sc injections of asfotase alfa are required to prevent HPP in mice, whereas nearly daily or thrice weekly sc injections are used to treat HPP patients. Viral vector delivery of mineral-targeting TNAP by this type of gene therapy might be an alternative to repetitive injections.
In 2011, Yamamoto et al. [134] demonstrated that a single sc iv injection of a lentiviral vector expressing mineral-targeting TNAP at birth permanently increased plasma TNAP levels in KO mice that survived more than 10 months and had normal physical activity, healthy appearance, no epileptic seizures, and radiographs showing significantly improved or preserved skeletal mineralization using this gene therapy. Also in 2011, Matsumoto et al. [135] demonstrated similar treatment effects, but using the adeno-associated virus serotype 8 (AAV8) vector that is more promising than lentiviral vectors for clinical trials. They expressed mineral-targeted TNAP and soluble, non-targeted TNAP tagged with the FLAG epitope. A single IV injection of $5 \times 10^{10}$ vector genomes of either TNAP into KO mice at day 1 of life prolonged survival and prevented the skeletal abnormalities, suggesting that sustained ALP activity in the circulation at some threshold level may prevent the manifestations of HPP.

In 2012, Sugano et al. [136] demonstrated the feasibility of fetal gene therapy for HPP by giving KO mouse fetuses, at 15 days gestation, a single transuterine intraperitoneal injection of AAV serotype 9 (AAV9) expressing mineral-targeted TNAP. After birth, these mice showed normal weight gain and seizure-free survival for at least 8 weeks.

ALP activities in plasma and bone were consistently high, and sustained mineralization was demonstrated on radiographs of the chest and forepaw.

Hence, viral vector delivery of mineral-targeted TNAP has potential to treat HPP with significantly reduced frequency of injections and cost of treatment.

**Concluding Remarks**

There has been substantial progress during the past decade in understanding TNAP and therefore in treating HPP patients. Clinical trials of EzRT using asfotase alfa (now approved as Strensiq™ in Japan, Canada, Europe, and the USA generally for pediatric-onset HPP) have shown skeletal, respiratory, and functional improvement as well as prevention of seizures in the most severe perinatal and infantile forms of the disease and attainment of good health in survivors of infantile HPP and with severe childhood HPP. Ongoing clinical trials are revealing aspects of HPP that we do not yet fully understand, such as its treatable muscle weakness, or that seemingly cannot be prevented such as craniosynostosis. Now that life-threatening and debilitating pediatric HPP is treatable using asfotase

**Fig. 8** Efficacy of asfotase alfa treatment in a 36-month-old girl (at therapy baseline) with life-threatening HPP. a She has a short, bowed femur detected in utero by ultrasound. b At 12 days-of-age, her chest radiograph showed thin, osteopenic ribs with lytic areas and fractures. c, d Images of the skull before and after 24 weeks of ENB-0040 treatment. Note the severe pan-suture closure, including a marked increase in “digital” markings (“beaten-copper” appearance). e The ribs at baseline were osteopenic and had fracture deformities with thin cortices. f By week 24 of treatment, the ribs were wider and better mineralized with sharper cortical margins and less deformity. g Improvement of the rickets with therapy is apparent. Images taken for the online supplementary data in [9] and reproduced with permission from The New England Journal of Medicine.
alfa, and the risks and benefits of this EzRT in managing HPP in adults require study. These patients may present unique challenges because vascular calcification can be a comorbidity of aging, diabetes mellitus, or chronic kidney disease. Binding of mineral-targeted TNAP to such sites of ectopic calcification could theoretically lead to cardiovascular complications [137]. It is not known if non-targeted ALPs will be useful alternatives. Safe viral vectors for delivery of mineral-targeted or soluble ALPs may streamline HPP treatment in the future.

Funding This study was funded by grant DE12889 from NIDCR, NIH (JLM), Shriners Hospitals for Children (MPW), The Clark and Mildred Cox Inherited Metabolic Bone Disease Fund (MPW), The hypophosphatasia Research Fund (MPW) and the Barnes-Jewish Hospital Foundation (MPW).

Compliance with Ethical Standards

Conflict of Interest JLM and MPW have received grant support, honoraria, and travel reimbursements from Alexion Pharmaceuticals, Cheshire, CT. JLM has received grant support and honoraria from AM-Pharma, Bunnik, The Netherlands.

Human and Animal Rights and Informed Consent All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References


Fig. 9 Efficacy of asfotase alfa in a 20-day-old (at therapy baseline) patient with life-threatening HPP. a This boy had shortened and bowed extremities and “fractures” detected by prenatal sonography at 17–18 weeks gestation. b Before asfotase alfa treatment, little or decreased mineral was present in the frontal, parietal, or occipital bones, skull base, facial bones, and sphenoid. c Before asfotase alfa, the femora were short, sclerotic, bowed, irregular, and lacked defined medullary cavities, cortices, and mineralized metaphyses and epiphyses. The fibulae were not calcified. After therapy, striking mineralization was evident. At week 24 of therapy, all areas showed striking remineralization. d The improvement in the left hand and wrist was remarkable. Images taken for the online supplementary data in [9] and reproduced with permission from The New England Journal of Medicine.
414 J. L. Millán, M. P. Whyte: Alkaline Phosphatase and Hypophosphatasia


